Industry Clinical Trials
A human subjects research study whose primary purpose is to assess the safety and/or efficacy in humans of a drug, device, diagnostic, treatment, preventive measure, or similar intervention through testing of the intervention on patients in a clinical setting.
Phase I: Researchers test a new drug or treatment in a small group of people for the first time to evaluate its safety, determine a safe dosage range, and identify side effects.
Phase II: The drug or treatment is given to a larger group of people to see if it is effective and to further evaluate its safety.
Phase III: The drug or treatment is given to large groups of people to confirm its effectiveness, monitor side effects, compare it to commonly used treatments, and collect information that will allow the drug or treatment to be used safely.
Phase IV: Studies are done after the drug or treatment has been marketed to gather information on the drug’s effect in various populations and any side effects associated with long-term use.
Other: A study that does not fall into Phase I-IV definition. Examples include: Expanded access, compassionate use, and humanitarian use studies.
Generally, industry sponsored clinical trials are funded by pharmaceutical companies and are based on its protocol. Often, these sponsors work with Contract Research Organizations (CROs) that act as a representative for the company.
When the protocol is developed by the investigator, the clinical trial is referred to as “Investigator-initiated”, regardless of funding source.
Most clinical trial sponsors require a confidentiality agreement (CDA) before sharing protocols or other proprietary information.
When asked to enter into a pre-clinical trial CDA, route a Non-Award Agreement eGC1 with the CDA attached to OSP for review and signature.
Review more information:
An investigator who signs a CDA is exposed to potential personal liabilities and if something goes wrong, the UW will not be obligated to provide representation. If an investigator wishes to enter into the CDA due to urgent circumstances, they may do so, but strictly in a personal capacity.
Some factors to consider:
- The investigator does not have authority to enter into a CDA on behalf of the UW.
- Length of the obligation to keep information confidential should be reasonable e.g. 5 years is typical.
- Term (effective dates) of the CDA itself does not need to be longer than a year. The CDA term is different than the confidentiality period.
- Scope of the CDA should cover only a single named clinical trial, protocol or drug, not possible future studies.
- The sponsor should be required to mark or clearly designate confidential information.
- These types of information must be listed as exceptions in the CDA:
- Information already known by the researcher,
- publicly available information,
- Information independently developed by the researcher.
- There is no transfer of Intellectual Property (IP) rights from the researcher or UW to the company.
- The CDA should not indicate an exclusive relationship with the company.
Submit the following documents on an eGC1 in SAGE and route to the Office of Sponsored Programs (OSP):
- Draft clinical trial agreement
- Draft clinical trial protocol
- Draft informed consent form (if available)
- Sponsor/CRO contact information
If this information is not complete on the eGC1,the agreement will be delayed until OSP receives them.
The UW has Master Clinical Trial Agreements with many pharmaceutical and medical device companies conducting clinical trial research.
Clinical Trial Budget
Clinical trial budgets are reviewed by UW Clinical Research Budget and Billing (CRBB). Once reviewed, CRBB sends approval to the PI and OSP.
Your project may be eligible for an Advance Budget Number while waiting for the contract or budget review to be finalized.
Please use the Advance Budget Number Eligibility Tool.
Industry-sponsored and industry-initiated human subjects research conducted by UW researchers is usually reviewed by one of the following Institutional Review Boards (IRBs):
- An independent IRB such as WIRB or Advarra
- The Cancer Consortium IRB (CC-IRB) operated by Fred Hutchinson Cancer Research Center (FHCRC)
IRB review fees and an HSD administrative fee may need to be included in the budget. See HSD’s website for more information about IRB review of industry sponsored research.
More information from the Human Subjects division:
The Office of Sponsored Programs has Master Clinical Trial Agreements with many pharmaceutical and medical device companies that conduct clinical trial research, including almost all of the major sponsors.
List of Master Clinical Trial Agreements (MCTA)
Review the list
|Bayer Healthcare Pharma, Inc.||25-Feb-20|
|Bristol Myers Squibb||31-Dec-18|
|Bristol Myers Squibb Medical Imaging||None|
|Edwards Lifesciences, LLC||None|
|Eisai Medical Research, Inc.||22-Sep-19|
|Eli Lilly and Company||None|
|EMD Serono, Inc.||None|
|Emergent Product Development||9-Dec-19|
|General Electric Co. (Comp. Research)||None|
|Jaeb Center for Health Research||31-Dec-18|
|Janssen Research & Development||18-Nov-18|
|Novartis Pharmaceuticals Corp.||20-Apr-20|
|SC Liver Research Consortium||None|
|Translational Breast Cancer Research
Consortium Master Member Agreement
** Master CTAs through the Prostate Cancer Clinical Trial Consortium, for members only.
|Algeta ASA **||None|
|BMS (PI-initiated trials only) **||None|
|ImaginAb, Inc. **||None|
|Kinex Pharmaceuticals **||None|